BUZZ-Icon falls on downbeat 2025 profit, revenue forecasts

Reuters

Jan 14, 2025

** Shares of Icon ICLR.O fall 8.5% to $199.50 premarket

** Contract research firm sees its 2025 adj EPS between $13 and $15

** The midpoint is lower than Wall Street estimates of $14.83 - LSEG

** The midpoint of co's 2025 rev outlook of $8.05 bln-$8.65 bln is also lower than estimates of $8.50 bln

** "Icon continues to navigate dynamic clinical development market conditions, as trial activity has been impacted by cautious spending from biopharma customers, in both the biotech and large pharma businesses," CEO Steve Cutler says

** "Overall, the guidance reflects a still-hesitant demand environment across both pharma and biotech, which will likely last for an additional 2-4 quarters" - brokerage Evervore ISI

** Co reaffirms 2024 adj EPS and rev outlooks

** ICLR stock fell 25.9% in 2024

(Reporting by Puyaan Singh)

((Puyaan.Singh@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2503575095"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503575095\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2503575095?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-14 22:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503575095","market":"us","top_or_hot":-1,"title":"BUZZ-Icon falls on downbeat 2025 profit, revenue forecasts","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Icon falls on downbeat 2025 profit, revenue forecasts</title></head><body><p>** Shares of Icon <span>ICLR.O</span> fall 8.5% to $199.50 premarket</p><p>** Contract research firm sees its <span>2025 adj EPS</span> between $13 and $15</p><p>** The midpoint is lower than Wall Street estimates of $14.83 - LSEG</p><p>** The midpoint of co's 2025 rev outlook of $8.05 bln-$8.65 bln is also lower than estimates of $8.50 bln</p><p>** \"Icon continues to navigate dynamic clinical development market conditions, as trial activity has been impacted by cautious spending from biopharma customers, in both the biotech and large pharma businesses,\" CEO Steve Cutler says</p><p>** \"Overall, the guidance reflects a still-hesitant demand environment across both pharma and biotech, which will likely last for an additional 2-4 quarters\" - brokerage Evervore ISI</p><p>** Co reaffirms 2024 adj EPS and rev outlooks</p><p>** ICLR stock fell 25.9% in 2024</p><p> (Reporting by Puyaan Singh)</p><p> ((Puyaan.Singh@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Icon falls on downbeat 2025 profit, revenue forecasts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Icon falls on downbeat 2025 profit, revenue forecasts\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-01-14 22:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Icon falls on downbeat 2025 profit, revenue forecasts</title></head><body><p>** Shares of Icon <span>ICLR.O</span> fall 8.5% to $199.50 premarket</p><p>** Contract research firm sees its <span>2025 adj EPS</span> between $13 and $15</p><p>** The midpoint is lower than Wall Street estimates of $14.83 - LSEG</p><p>** The midpoint of co's 2025 rev outlook of $8.05 bln-$8.65 bln is also lower than estimates of $8.50 bln</p><p>** \"Icon continues to navigate dynamic clinical development market conditions, as trial activity has been impacted by cautious spending from biopharma customers, in both the biotech and large pharma businesses,\" CEO Steve Cutler says</p><p>** \"Overall, the guidance reflects a still-hesitant demand environment across both pharma and biotech, which will likely last for an additional 2-4 quarters\" - brokerage Evervore ISI</p><p>** Co reaffirms 2024 adj EPS and rev outlooks</p><p>** ICLR stock fell 25.9% in 2024</p><p> (Reporting by Puyaan Singh)</p><p> ((Puyaan.Singh@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ICLR","symbol_name":"ICON plc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250114:nL4N3OA14B:1","article_id":"2503575095","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503575095","pubTimestamp":1736863707,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Icon falls on downbeat 2025 profit, revenue forecasts** Shares of Icon ICLR.O fall 8.5% to $199.50 premarket** Contract research firm sees its 2025 adj EPS between $13 and $15** The midpoint is lower than Wall Street estimates of $14.83 - LSEG** The midpoint of co's 2025 rev outlook of $8.05 bln-$8.65 bln is also lower than estimates of $8.50 bln** \"Icon continues to navigate dynamic clinical development market conditions, as trial activity has been impacted by cautious spending from biopharma customers, in both the biotech and large pharma businesses,\" CEO Steve Cutler says** \"Overall, the guidance reflects a still-hesitant demand environment across both pharma and biotech, which will likely last for an additional 2-4 quarters\" - brokerage Evervore ISI** Co reaffirms 2024 adj EPS and rev outlooks** ICLR stock fell 25.9% in 2024  ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ICLR":"ICON plc"},"translate_title":"BUZZ-Icon因2025年利润和收入预测悲观而下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ICLR":0.9},"content_text":"BUZZ-Icon falls on downbeat 2025 profit, revenue forecasts** Shares of Icon ICLR.O fall 8.5% to $199.50 premarket** Contract research firm sees its 2025 adj EPS between $13 and $15** The midpoint is lower than Wall Street estimates of $14.83 - LSEG** The midpoint of co's 2025 rev outlook of $8.05 bln-$8.65 bln is also lower than estimates of $8.50 bln** \"Icon continues to navigate dynamic clinical development market conditions, as trial activity has been impacted by cautious spending from biopharma customers, in both the biotech and large pharma businesses,\" CEO Steve Cutler says** \"Overall, the guidance reflects a still-hesitant demand environment across both pharma and biotech, which will likely last for an additional 2-4 quarters\" - brokerage Evervore ISI** Co reaffirms 2024 adj EPS and rev outlooks** ICLR stock fell 25.9% in 2024 (Reporting by Puyaan Singh) ((Puyaan.Singh@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}